Sage Journals: Discover world-class research

Abstract

BACKGROUND:

Periprosthetic joint infection is a major complication of total joint arthroplasty, with treatment requiring a two-stage exchange procedure and 6 weeks of systemic antibiotics. However, depending on the infection site, intravenous delivery of antibiotics like vancomycin (VCM) can have poor tissue transferability, thus reducing their therapeutic effect.

OBJECTIVE:

This study demonstrates the 24-week in vivo release profile and antibacterial activity of VCM from calcium phosphate cement impregnated with VCM (CPC/VCM) and compares them with those from polymethylmethacrylate impregnated with VCM (PMMA/VCM).

METHODS:

Rats were implanted with the test specimens between the fascia and quadriceps. After implantation for 24 weeks, the test specimens were removed and residual VCM was extracted to calculate the concentration of VCM released into rat tissues. We also examined the antibacterial activity of releasable VCM from the removed test specimens by placing them directly onto the surface of agar.

RESULTS:

CPC/VCM released greater concentrations of VCM for a longer period of time within the 24 weeks than PMMA/VCM. Moreover, CPC/VCM released 1.4 to 26.1-fold more VCM than PMMA/VCM. Using Staphylococcus aureus, antibacterial activity was logarithmically correlated with VCM concentration across the entire concentration range tested (12.5–800 μg/mL). While the area within which inhibition was observed—the inhibition zone—for both CPC/VCM and PMMA/VCM formed and gradually shrank with time after implantation, that for CPC/VCM was significantly larger than that for PMMA/VCM in each week after implantation.

CONCLUSION:

CPC/VCM releases greater amounts of VCM with antibacterial activity for longer periods of time than PMMA/VCM, suggesting that CPC is effective for facilitating the release of antibiotics for local action in patients with established postoperative infection.

Keywords

Antibacterial activity calcium phosphate cement polymethylmethacrylate vancomycin

Get full access to this article

View all access options for this article.

References

Gimeno

Pinczowski

Perez

Giorello

Martinez

M.A.

, A controlled antibiotic release system to prevent orthopedic-implant associated infections: An in vitro study, Eur. J. Pharm. Biopharm. 96 (2015), 264–271.

Uckay

Hoffmeyer

Lew

and Pittet

, Prevention of surgical site infections in orthopaedic surgery and bone trauma: State-of-the-art update, J. Hosp. Infect. 84 (2013), 5–12.

Ocguder

Firat

Tecimel

Solak

and Bozkurt

, Two-stage total infected knee arthroplasty treatment with articulating cement spacer, Arch. Orthop. Trauma Surg. 130 (2010), 719–725.

Scott

I.R.

Stockley

and Getty

C.J.

, Exchange arthroplasty for infected knee replacements. A new two-stage method, J. Bone Joint Surg. Br. 75 (1993), 28–31.

Cruciani

Gatti

Lazzarini

Furlan

Broccali

, Penetration of vancomycin into human lung tissue, J. Antimicrob. Chemother. 38 (1996), 865–869.

Pitto

R.P.

and Spika

I.A.

, Antibiotic-loaded bone cement spacers in two-stage management of infected total knee arthroplasty, Int. Orthop. 28 (2004), 129–133.

Iwakura

Lee

S.Y.

Niikura

Miwa

Sakai

, Gentamycin-impregnated calcium phosphate cement for calcaneal osteomyelitis: A case report, J. Orthop. Surg. (Hong Kong) 22 (2014), 437–439.

Marks

K.E.

Nelson

C.L.

and Lautenschlager

E.P.

, Antibiotic-impregnated acrylic bone cement, J. Bone Joint Surg. Am. 58 (1976), 358–364.

Murray

W.R.

, Use of antibiotic-containing bone cement, Clin. Orthop. Relat. Res. (1984), 89–95.

10.

Schurman

D.J.

Trindade

Hirshman

H.P.

Moser

Kajiyama

, Antibiotic-acrylic bone cement composites. Studies of gentamicin and Palacos, J. Bone Joint Surg. Am. 60 (1978), 978–984.

11.

Uchiyama

Takahira

Fukushima

Moriya

Yamamoto

, Two-stage revision total hip arthroplasty for periprosthetic infections using antibiotic-impregnated cement spacers of various types and materials, Sci. World J. 2013 (2013), 147248.

12.

Wahlig

and Dingeldein

, Antibiotics and bone cements. Experimental and clinical long-term observations, Acta Orthop. Scand. 51 (1980), 49–56.

13.

Urabe

Naruse

Hattori

Hirano

Uchida

, In vitro comparison of elution characteristics of vancomycin from calcium phosphate cement and polymethylmethacrylate, J. Orthop. Sci. 14 (2009), 784–793.

14.

Uchida

Sugo

Nakajima

Nakawaki

Takano

, In vivo release of vancomycin from calcium phosphate cement, Biomed. Res. Int. 2018 (2018), 4560647.

15.

Kuzyk

P.R.

Dhotar

H.S.

Sternheim

Gross

A.E.

Safir

, Two-stage revision arthroplasty for management of chronic periprosthetic hip and knee infection: Techniques, controversies, and outcomes, J. Am. Acad. Orthop. Surg. 22 (2014), 153–164.

16.

Masri

B.A.

Duncan

C.P.

and Beauchamp

C.P.

, Long-term elution of antibiotics from bone-cement: An in vivo study using the prosthesis of antibiotic-loaded acrylic cement (PROSTALAC) system, J. Arthroplasty 13 (1998), 331–338.

17.

Niikura

Lee

S.Y.

Iwakura

Sakai

Kuroda

, Antibiotic-impregnated calcium phosphate cement as part of a comprehensive treatment for patients with established orthopaedic infection, J. Orthop. Sci. 21 (2016), 539–545.

18.

Priest

D.H.

and Peacock Jr.

J.E.

, Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: Clinical features and therapeutic outcomes, South Med. J. 98 (2005), 854–862.

19.

Anagnostakos

Kelm

Regitz

Schmitt

and Jung

, In vitro evaluation of antibiotic release from and bacteria growth inhibition by antibiotic-loaded acrylic bone cement spacers, J. Biomed. Mater. Res. B Appl. Biomater. 72 (2005), 373–378.

20.

Kelm

Regitz

Schmitt

Jung

and Anagnostakos

, In vivo and in vitro studies of antibiotic release from and bacterial growth inhibition by antibiotic-impregnated polymethylmethacrylate hip spacers, Antimicrob. Agents Chemother. 50 (2006), 332–335.

21.

Japanese Standards A, Antimicrobial products: Test for antimicrobial activity and efficacy. Japanese Industrial Standard 2000; JIS Z 2801 (2000).

22.

Baker

G.L.

Vogel

E.B.

and Smith

M.R.

, Glass transitions in polylactides, Polym. Rev. 48 (2008), 64–84.

23.

Sasaki

Ishibashi

Katano

Nagumo

and Toh

, In vitro elution of vancomycin from calcium phosphate cement, J. Arthroplasty 20 (2005), 1055–1059.

24.

Zupancic

Sinha-Ray

Kristl

and Yarin

A.L.

, Long-term sustained ciprofloxacin release from PMMA and hydrophilic polymer blended nanofibers, Mol. Pharm. 13 (2016), 295–305.

25.

Sabokbar

Fujikawa

Murray

D.W.

and Athanasou

N.A.

, Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption, Ann. Rheum. Dis. 57 (1998), 614–618.

26.

Schnieders

Gbureck

Vorndran

Schossig

and Kissel

, The effect of porosity on drug release kinetics from vancomycin microsphere/calcium phosphate cement composites, J. Biomed. Mater. Res. B Appl. Biomater. 99 (2011), 391–398.

27.

Hofmann

A.A.

Goldberg

Tanner

A.M.

and Kurtin

S.M.

, Treatment of infected total knee arthroplasty using an articulating spacer: 2- to 12-year experience, Clin. Orthop. Relat. Res. (2005), 125–131.

28.

Ellington

J.K.

Harris

Hudson

M.C.

Vishin

Webb

L.X.

, Intracellular Staphylococcus aureus and antibiotic resistance: Implications for treatment of staphylococcal osteomyelitis, J. Orthop. Res. 24 (2006), 87–93.

29.

Gould

J.C.

, The determination of bacterial sensitivity to antibiotics, Edinb. Med. J. 59 (1952), 178–199.

30.

Carli

A.V.

Sethuraman

A.S.

Bhimani

S.J.

Ross

F.P.

and Bostrom

M.P.G.

, Selected heat-sensitive antibiotics are not inactivated during polymethylmethacrylate curing and can be used in cement spacers for periprosthetic joint infection, J. Arthroplasty 33 (2018), 1930–1935.

31.

Abd El-Aziz

N.K.

Abd EI-Hamid

M.I.

Bendray

M.M.

El-Azazy

A.A.

and Ammar

A.M.

, Existence of vancomycin resistance among methicillin resistant S. aureus recovered from animal and human sources in Egypt, Slov. Vet. Res. 55 (2018), 221–230.

32.

Howden

B.P.

Ward

P.B.

Charles

P.G.

Korman

T.M.

Fuller

, Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility, Clin. Infect. Dis. 38 (2004), 521–528.

33.

Forouzesh

Moise

P.A.

and Sakoulas

, Vancomycin ototoxicity: A reevaluation in an era of increasing doses, Antimicrob. Agents Chemother. 53 (2009), 483–486.

34.

Aljefri

D.M.

Avedissian

S.N.

Rhodes

N.J.

Postelnick

M.J.

Nguyen

, Vancomycin area under the curve and acute kidney injury: A meta-analysis, Clin. Infect. Dis. 69 (2019), 1881–1887.

35.

Lodise

T.P.

Patel

Lomaestro

B.M.

Rodvold

K.A.

and Drusano

G.L.

, Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients, Clin. Infect. Dis. 49 (2009), 507–514.

36.

Rybak

M.J.

Lodise

T.P.

Levine

D.P.

Bradley

J.S.

, Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists, Am. J. Health Syst. Pharm. 77 (2020), 835–864.